Cat. #161784
TOV-3291G cell line
Cat. #: 161784
Availability: 8-10 weeks
Organism: Human
Tissue: Derived from high-grade serous tumors
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de Luniversité de Montréal
Primary Citation: Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: TOV-3291G cell line
- Alternate name: TOV-3291G
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Gender: Female
- Tissue: Derived from high-grade serous tumors
- Donor: Age of diagnosis: 59; BRCA hereditary status: negative Grade 3 Stage IIIC; Mutations: TP53, CDK12; Pre-treatment
- Morphology: Formed loosely compact spheroids with irregular margins
- Growth properties: Adherent
- Crispr: No
- Receptors of note: No
- Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serous solid tumors. TOV3291G harbors a TP53 mutation, a comlex CNA pattern, and has a CDK12 mutation.
- Production details: Established using the Scrape method where tumor tissue was scraped into a 100mm plate with complete OSE medium and maintained for 40 days with medium replaced weekly.
- Additional notes: Patient 3291 was age 59 at diagnosis and BRCA hereditary status was negative. Their first line treatment was surgery followed by cisplatin/taxol. No previous personal history of cancer and yera of sampling was 2007.
Handling
- Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
- Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
- Cultured in antibiotics: Amphotericin B and Gentamicin
References
- Vias et al. 2023. Elife. 11
- 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
- 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
- 15(9):2566. PMID: 37174032
